Home » GlaxoSmithKline Submits New Application for Synflorix in EU
GlaxoSmithKline Submits New Application for Synflorix in EU
GlaxoSmithKline said it has submitted a regulatory application in the European Union seeking approval of an additional indication for Synflorix, a paediatric pneumococcal vaccine, for the active immunization against pneumonia caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 5 years of age.
Fox Business
Fox Business
Upcoming Events
-
07May
-
14May
-
30May